Programmable nucleic acid nanoparticles (NANPs) with precisely controlled functional compositions can regulate the conditional activation of various biological pathways and responses in human cells. However, the intracellular delivery of NANPs alone is hindered by their susceptibility to nuclease activity and inefficient crossing of biological membranes. In this work, we optimized the internalization and therapeutic performance of several representative NANPs delivered with mesoporous silica nanoparticles (MSNPs) tailored for efficient electrostatic association with NANPs. We compared the immunostimulatory properties of different NA-MS-NP complexes formed with globular, planar, and fibrous NANPs and demonstrated the maximum immunostimulation for globular NANPs. As a proof of concept, we assessed the specific gene silencing by NA-MS-NP complexes functionalized with siRNA targeting green fluorescent protein expressed in triple-negative human breast cancer cells. We showed that the fibrous NANPs have the highest silencing efficiency when compared to globular or planar counterparts. Finally, we confirmed the multimodal ability of MSNPs to co-deliver a chemotherapy drug, doxorubicin, and NANPs targeting apoptosis regulator gene BCL2 in triple-negative breast cancer and melanoma cell lines. Overall, the combination of NANPs and MSNPs may become a new promising approach to efficiently treat cancer and other diseases via the simultaneous targeting of various pathways.
Programmable nucleic acid nanoparticles (class="Gene">NANPs) with class="Chemical">precisely controlled functional comclass="Chemical">positions can regulate the conditional activation of various biological class="Chemical">pathways and resclass="Chemical">ponses in class="Chemical">pan class="Species">human cells. However, the intracellular delivery of NANPs alone is hindered by their susceptibility to nuclease activity and inefficient crossing of biological membranes. In this work, we optimized the internalization and therapeutic performance of several representative NANPs delivered with mesoporous silica nanoparticles (MSNPs) tailored for efficient electrostatic association with NANPs. We compared the immunostimulatory properties of different NA-MS-NP complexes formed with globular, planar, and fibrous NANPs and demonstrated the maximum immunostimulation for globular NANPs. As a proof of concept, we assessed the specific gene silencing by NA-MS-NP complexes functionalized with siRNA targeting green fluorescent protein expressed in triple-negative humanbreast cancer cells. We showed that the fibrous NANPs have the highest silencing efficiency when compared to globular or planar counterparts. Finally, we confirmed the multimodal ability of MSNPs to co-deliver a chemotherapy drug, doxorubicin, and NANPs targeting apoptosis regulator gene BCL2 in triple-negative breast cancer and melanoma cell lines. Overall, the combination of NANPs and MSNPs may become a new promising approach to efficiently treat cancer and other diseases via the simultaneous targeting of various pathways.
Entities:
Keywords:
combination therapy; doxorubicin; melanoma; mesoporous silica nanoparticles (MSNPs); nucleic acid nanoparticles (NANPs); small interfering RNA; triple-negative breast cancer
Authors: Enping Hong; Justin R Halman; Ankit B Shah; Emil F Khisamutdinov; Marina A Dobrovolskaia; Kirill A Afonin Journal: Nano Lett Date: 2018-06-20 Impact factor: 11.189
Authors: Kirill A Afonin; Wojciech Kasprzak; Eckart Bindewald; Praneet S Puppala; Alex R Diehl; Kenneth T Hall; Tae Jin Kim; Michael T Zimmermann; Robert L Jernigan; Luc Jaeger; Bruce A Shapiro Journal: Methods Date: 2013-11-01 Impact factor: 3.608
Authors: Luda S Shlyakhtenko; Alexander A Gall; Alexander Filonov; Zoran Cerovac; Alexander Lushnikov; Yuri L Lyubchenko Journal: Ultramicroscopy Date: 2003 Oct-Nov Impact factor: 2.689
Authors: Kirill A Afonin; Wojciech K Kasprzak; Eckart Bindewald; Maria Kireeva; Mathias Viard; Mikhail Kashlev; Bruce A Shapiro Journal: Acc Chem Res Date: 2014-04-23 Impact factor: 22.384
Authors: Da Shi; Damian Beasock; Adam Fessler; Janos Szebeni; Julia Y Ljubimova; Kirill A Afonin; Marina A Dobrovolskaia Journal: Adv Drug Deliv Rev Date: 2021-12-10 Impact factor: 15.470
Authors: Morgan Chandler; Brittany Johnson; Emil Khisamutdinov; Marina A Dobrovolskaia; Joanna Sztuba-Solinska; Aliasger K Salem; Koen Breyne; Roger Chammas; Nils G Walter; Lydia M Contreras; Peixuan Guo; Kirill A Afonin Journal: ACS Nano Date: 2021-10-22 Impact factor: 18.027
Authors: Prabhat Tripathi; Morgan Chandler; Christopher Michael Maffeo; Ali Fallahi; Amr Makhamreh; Justin Halman; Aleksei Aksimentiev; Kirill A Afonin; Meni Wanunu Journal: Nanoscale Date: 2022-05-16 Impact factor: 8.307
Authors: Renata F Saito; Maria Cristina Rangel; Justin R Halman; Morgan Chandler; Luciana Nogueira de Sousa Andrade; Silvina Odete-Bustos; Tatiane Katsue Furuya; Alexis Germán Murillo Carrasco; Adriano B Chaves-Filho; Marcos Y Yoshinaga; Sayuri Miyamoto; Kirill A Afonin; Roger Chammas Journal: Nanomedicine Date: 2021-06-24 Impact factor: 6.096